Ovarian stimulation with gonadotropin-releasing hormone (GnRH) analogue improves the in vitro fertilization (IVF) pregnancy rate with both transvaginal and laparoscopic oocyte recovery
- PMID: 2150203
- DOI: 10.1007/BF01130589
Ovarian stimulation with gonadotropin-releasing hormone (GnRH) analogue improves the in vitro fertilization (IVF) pregnancy rate with both transvaginal and laparoscopic oocyte recovery
Abstract
The relative impact of ovarian stimulation protocol and oocyte retrieval technique on success rates of in vitro fertilization program was studied in 200 patients. Sixty-three patients received gonadotropin-releasing hormone analogue (GnRHa) with human menopausal gonadotropin (hMG), and 137 received hMG only. The GnRHa + hMG protocol resulted in higher pregnancy rates than the hMG-only protocol (19.0 vs 9.5%, respectively; P less than 0.01) despite a lower cleavage rate. Oocyte retrieval was performed via laparoscopy in 100 patients and transvaginally in 100 patients. The number of oocytes recovered per cycle was 6.1 +/- 3.9 with laparoscopy and 7.0 +/- 3.1 transvaginally. Pregnancy rates were similar for both retrieval techniques (13 and 12%, respectively). A breakdown of these results showed that the advantage for the GnRHa + hMG protocol was not affected by the oocyte retrieval technique. A comparison of simultaneous blood and follicular fluid pH measured every 10 min during laparoscopy and transvaginal oocyte recovery revealed a constant decline in follicular fluid pH during laparoscopy, while no changes were observed during the vaginal procedure. We conclude that the improvement in in vitro fertilization results during the period of our study is due primarily to the introduction of GnRHa + hMG protocol rather than the method of oocyte retrieval.
Similar articles
-
Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.Gynecol Obstet Invest. 1990;29(2):140-4. doi: 10.1159/000293320. Gynecol Obstet Invest. 1990. PMID: 2139861
-
The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET).J In Vitro Fert Embryo Transf. 1990 Dec;7(6):327-31. doi: 10.1007/BF01130584. J In Vitro Fert Embryo Transf. 1990. PMID: 2127603
-
Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase--a function of improved embryo quality.J Assist Reprod Genet. 2001 Apr;18(4):197-204. doi: 10.1023/a:1009476411762. J Assist Reprod Genet. 2001. PMID: 11432110 Free PMC article. Clinical Trial.
-
Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jun;55(6):452-6. Zhonghua Yi Xue Za Zhi (Taipei). 1995. PMID: 7634183 Clinical Trial.
-
Oocyte retrieval for in vitro fertilization.Ann Biol Clin (Paris). 1987;45(3):351-7. Ann Biol Clin (Paris). 1987. PMID: 2959179 Review.
Cited by
-
In vitro fertilization treatment for severe male factor: a comparative study of intracytoplasmic sperm injection with testicular sperm extraction and with spermatozoa from ejaculate.J Assist Reprod Genet. 1998 Jul;15(6):386-9. doi: 10.1023/a:1022537117578. J Assist Reprod Genet. 1998. PMID: 9673884 Free PMC article.
-
The prognostic importance of the number of oocytes retrieved and estradiol levels in poor and normal responders in in vitro fertilization (IVF) treatment.J Assist Reprod Genet. 1992 Jun;9(3):228-32. doi: 10.1007/BF01203818. J Assist Reprod Genet. 1992. PMID: 1525451
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical